Michail_Petrov-96 Ventyx Biosciences ( NASDAQ: VTYX ) reported encouraging preclinical results for its anti-obesity drug candidate VTX3232 as both a monotherapy and in combination with the GLP-1 drug semaglutide. The biotech company said VTX3232 as a monotherapy showed a reduction in body weight, body fat content, food consumption, liver triglycerides, and liver fat deposits, as well as improved insulin resistance, cardiometabolic parameters, and systemic inflammation biomarkers. Ventyx added that VTX3232 in combination with the GLP-1 drug semaglutide demonstrated additive effects across key endpoints compared to semaglutide or VTX3232 alone, according to a statement .
The company plans to initiate a Phase 2a study of VTX32323 in patients with obesity and other cardiovascular risk factors in Q2. Semaglutide is marketed by Novo Nordisk under the brand names Wegovy and Ozempic. More on Ventyx Biosciences Ventyx Biosciences, Inc.
(VTYX) Q1 2024 Earnings Call Transcript Ventyx Pivots To Obesity Amid Transformation Ventyx Biosciences gets new operations chief Ventyx Biosciences drops 3%, stockholders to sell ~11.17M shares Seeking Alpha’s Quant Rating on Ventyx Biosciences.
